PHARMAENGINE INC
PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 3 projects in the pipeline. ONIVYDE® (PEP02, MM-398, nal-IRI), a new formulation of an anti-cancer drug (irinotecan) for the patients with gemcitabine-treated metastatic pancreatic cancer, was approved by both the US FDA and Taiwan FDA in 2015, European Medicines Agency (EMA) in 2016, Korea MFDS and Singapore HAS in 2017. PEP503 (NBTXR3), a nanoparticle working as a radio-enhancer, is in a positive global pivotal trial of soft tissue sarcoma, the other ongoing studies are in Phase I/II trial in head and neck cancerand rectal cancer in Taiwan. PEP06, a new chemical entity (NCE) for cancer treatment, is currently in the pre-clinical stage.
PHARMAENGINE INC
Industry:
Biotechnology
Founded:
2003-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.pharmaengine.com
Status:
Active
Contact:
+886 2 2515–8228
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail ASP.NET IIS Sectigo SSL Sectigo Domain SSL ASP.NET 4.0 IIS 8 Network Solutions DNS
Similar Organizations
Nyken Theraputics
Nyken is a biopharmaceutical company
Oncoscience
Oncoscience is a biopharmaceutical company
Targepeutics
Targepeutics Inc. is a biopharmaceutical company.
Official Site Inspections
http://www.pharmaengine.com Semrush global rank: 3.39 M Semrush visits lastest month: 4.62 K
- Host name: so203-155.asiawhere.com
- IP address: 219.84.203.155
- Location: Taiwan
- Latitude: 23.5
- Longitude: 121
- Timezone: Asia/Taipei
More informations about "PharmaEngine Inc"
Overview | PharmaEngine, Inc.
Internal Audit Organization and Operation. ... Audit Office precisely performs audits according to the plan in order to evaluate how the internal control system of PharmaEngine is enforced and the scripts and related materials are enclosed …See details»
Company Profile | PharmaEngine, Inc.
PharmaEngine focuses on oncology therapies. Our commercial product, ONIVYDE® is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the …See details»
PharmaEngine Inc - Crunchbase Company Profile
PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 3 projects in the pipeline. ONIVYDE® (PEP02, …See details»
PharmaEngine, Inc.
PharmaEngine announces first patient dosed in Phase I trial of PEP07 for solid tumor cancers. 2024-03-24. ONIVYDE® obtains positive opinion from EMA's CHMP for new regimen in First-line Treatment of Metastatic PDAC. More. …See details»
PharmaEngine Company Profile 2024: Stock Performance
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no …See details»
PharmaEngine Inc - LinkedIn
PharmaEngine Inc. (Taipei Exchange: stock code 4162.TWO) began operations in 2003, is a commercial stage pharmaceutical company dedicated to developing medicines for cancer …See details»
PharmaEngine, Inc. (TPEX: 4162) Company Profile & Overview
Nov 8, 2024 PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a …See details»
PharmaEngine, Inc. Company Profile - Taiwan, China - EMIS
Jul 5, 2024 PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003, and funded by TTY Biopharm and Taiwan venture capitals. PharmaEngine adopts the …See details»
Company PharmaEngine, Inc. - MarketScreener.com
Jan 18, 2018 PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is …See details»
PharmaEngine Inc - Contacts, Employees, Board Members
PharmaEngine, Inc. is a biopharmaceutical company. Unlock even more features with Crunchbase ProSee details»
PharmaEngine, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore PharmaEngine, Inc. with its drug pipeline, therapeutic area, technology platform, 12 clinical trials, 13 news, and 13 literature, Disease Domain:Neoplasms, Endocrinology and …See details»
PharmaEngine - Pharmaceutical Companies Database - ICH GCP
PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 2 projects in the pipeline. ONIVYDE® (PEP02, MM-398, nal-IRI), a new formulation …See details»
PharmaEngine Company Profile - Craft
PharmaEngine (智擎生技製藥) is a biopharmaceutical company focusing on the development of new drugs for the treatment of cancer diseases. It offers ONIVYDE, a formulation of an anti …See details»
PharmaEngine - Overview, News & Similar companies - ZoomInfo
Mar 4, 2021 Who is PharmaEngine. About PharmaEngine (TWO: 4162) PharmaEngine, Inc. is a commercial stage oncology company headquartered in Taipei,Taiwan. PharmaEngine focuses …See details»
PharmaEngine, Inc. Company Profile & Data: stocks, market cap ...
PharmaEngine, Inc., a biopharmaceutical company, engages in the development and licensing of drugs and therapeutic drugs for treating cancer diseases in Taiwan and Europe. It is …See details»
PharmaEngine - Products, Competitors, Financials, Employees ...
PharmaEngine primarily engages in the pharmaceutical industry, with a particular emphasis on oncology drug development. It was founded in 2003 and is based in Taipei, Taiwan. …See details»
Fundamentals | PharmaEngine, Inc.
PharmaEngine announces first patient dosed in Phase I trial of PEP07 for solid tumor cancers. 2024-03-24. ONIVYDE® obtains positive opinion from EMA's CHMP for new regimen in First …See details»
PharmaEngine, Inc. ESG Risk Rating - sustainalytics.com
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no …See details»
Sustainability Report - pharmaengine.com
Communication, PharmaEngine published the first 2011 Corporate Social Responsibility Report in 2012 (renamed to Sustainability Report in 2021) and this year is the twelfth consecutive year …See details»